The FDA has approved Dabigatran (Pradaxa) for the prevention of stroke associated with Afib. Dabigatran is a direct oral thrombin inhibitor, which unlike warfarin, does not require any specific monitoring (FDA site). The RE-LY trial found dabigatran was non-inferior to warfarin for the prevention of stroke in Afib (abstract)
Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.